Jurgen B Bulitta

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1126019/publications.pdf

Version: 2024-02-01

160 papers	6,139 citations	61984 43 h-index	95266 68 g-index
174 all docs	174 docs citations	174 times ranked	5778 citing authors

#	Article	IF	Citations
1	Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing. Pharmacotherapy, 2010, 30, 1279-1291.	2.6	340
2	Penetration of Antibacterials into Bone. Clinical Pharmacokinetics, 2009, 48, 89-124.	3.5	252
3	Pharmacokinetic/Pharmacodynamic Investigation of Colistin against Pseudomonas aeruginosa Using an In Vitro Model. Antimicrobial Agents and Chemotherapy, 2010, 54, 3783-3789.	3.2	150
4	Population Pharmacokinetics and Pharmacodynamics of Continuous versus Short-Term Infusion of Imipenem-Cilastatin in Critically Ill Patients in a Randomized, Controlled Trial. Antimicrobial Agents and Chemotherapy, 2007, 51, 3304-3310.	3.2	138
5	Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	124
6	Attenuation of Colistin Bactericidal Activity by High Inoculum of Pseudomonas aeruginosa Characterized by a New Mechanism-Based Population Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2010, 54, 2051-2062.	3.2	119
7	Combination therapy for carbapenem-resistant Gram-negative bacteria. Expert Review of Anti-Infective Therapy, 2013, 11, 1333-1353.	4.4	112
8	Development of a New Pre- and Post-Processing Tool (SADAPT-TRAN) for Nonlinear Mixed-Effects Modeling in S-ADAPT. AAPS Journal, 2011, 13, 201-211.	4.4	111
9	Clinically Relevant Plasma Concentrations of Colistin in Combination with Imipenem Enhance Pharmacodynamic Activity against Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula. Antimicrobial Agents and Chemotherapy, 2011, 55, 5134-5142.	3.2	109
10	Systematic Comparison of the Population Pharmacokinetics and Pharmacodynamics of Piperacillin in Cystic Fibrosis Patients and Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2007, 51, 2497-2507.	3.2	108
11	Synergistic Killing of Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula by Colistin Combined with Doripenem in an In Vitro Pharmacokinetic/Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2011, 55, 5685-5695.	3.2	107
12	Phase 2, Randomized, Double-Blind, Dose-Ranging Study Evaluating the Safety, Tolerability, Population Pharmacokinetics, and Efficacy of Oral Torezolid Phosphate in Patients with Complicated Skin and Skin Structure Infections. Antimicrobial Agents and Chemotherapy, 2011, 55, 583-592.	3.2	107
13	Ertapenem Pharmacokinetics and Impact on Intestinal Microflora, in Comparison to Those of Ceftriaxone, after Multiple Dosing in Male and Female Volunteers. Antimicrobial Agents and Chemotherapy, 2004, 48, 3765-3772.	3.2	100
14	The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. Intensive Care Medicine, 2017, 43, 1021-1032.	8.2	100
15	Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units. Journal of Antimicrobial Chemotherapy, 2006, 58, 987-993.	3.0	96
16	Clinical Population Pharmacokinetics and Toxicodynamics of Linezolid. Antimicrobial Agents and Chemotherapy, 2014, 58, 2334-2343.	3.2	96
17	Synergistic Activity of Colistin and Rifampin Combination against Multidrug-Resistant Acinetobacter baumannii in an In Vitro Pharmacokinetic/Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2013, 57, 3738-3745.	3.2	94
18	Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime against Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2009, 53, 46-56.	3.2	88

#	Article	IF	Citations
19	Evaluation by Monte Carlo Simulation of the Pharmacokinetics of Two Doses of Meropenem Administered Intermittently or as a Continuous Infusion in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2005, 49, 1881-1889.	3.2	87
20	The Combination of Colistin and Doripenem Is Synergistic against Klebsiella pneumoniae at Multiple Inocula and Suppresses Colistin Resistance in an In Vitro Pharmacokinetic/Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2012, 56, 5103-5112.	3.2	85
21	Performance and Robustness of the Monte Carlo Importance Sampling Algorithm Using Parallelized S-ADAPT for Basic and Complex Mechanistic Models. AAPS Journal, 2011, 13, 212-226.	4.4	83
22	Polymyxin Resistance in Acinetobacter baumannii: Genetic Mutations and Transcriptomic Changes in Response to Clinically Relevant Dosage Regimens. Scientific Reports, 2016, 6, 26233.	3.3	82
23	Effects of grapefruit juice on the pharmacokinetics of sildenafil. Clinical Pharmacology and Therapeutics, 2002, 71, 21-29.	4.7	77
24	Two Mechanisms of Killing of Pseudomonas aeruginosa by Tobramycin Assessed at Multiple Inocula via Mechanism-Based Modeling. Antimicrobial Agents and Chemotherapy, 2015, 59, 2315-2327.	3.2	76
25	PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin. Journal of Controlled Release, 2013, 172, 128-136.	9.9	74
26	Quantifying Subpopulation Synergy for Antibiotic Combinations via Mechanism-Based Modeling and a Sequential Dosing Design. Antimicrobial Agents and Chemotherapy, 2013, 57, 2343-2351.	3.2	68
27	Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance. Antimicrobial Agents and Chemotherapy, 2016, 60, 3921-3933.	3.2	66
28	Population Pharmacokinetics at Two Dose Levels and Pharmacodynamic Profiling of Flucloxacillin. Antimicrobial Agents and Chemotherapy, 2007, 51, 3290-3297.	3.2	63
29	Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance. Journal of Antimicrobial Chemotherapy, 2015, 70, 1434-1442.	3.0	60
30	High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant Acinetobacter baumannii in a Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	60
31	Resistance Emergence Mechanism and Mechanism of Resistance Suppression by Tobramycin for Cefepime for Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2012, 56, 231-242.	3.2	52
32	Polymyxin Combinations: Pharmacokinetics and Pharmacodynamics for Rationale Use. Pharmacotherapy, 2015, 35, 34-42.	2.6	52
33	Novel Approach To Optimize Synergistic Carbapenem-Aminoglycoside Combinations against Carbapenem-Resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2015, 59, 2286-2298.	3.2	52
34	Distinguishing Antimicrobial Models with Different Resistance Mechanisms via Population Pharmacodynamic Modeling. PLoS Computational Biology, 2016, 12, e1004782.	3.2	50
35	Polymyxin Combinations Combat Escherichia coli Harboring mcr-1 and bla _{NDM-5} : Preparation for a Postantibiotic Era. MBio, 2017, 8, .	4.1	50
36	Pharmacodynamics of Vancomycin at Simulated Epithelial Lining Fluid Concentrations against Methicillin-Resistant Staphylococcus aureus (MRSA): Implications for Dosing in MRSA Pneumonia. Antimicrobial Agents and Chemotherapy, 2009, 53, 3894-3901.	3.2	49

#	Article	IF	Citations
37	The Lymphatic System Plays a Major Role in the Intravenous and Subcutaneous Pharmacokinetics of Trastuzumab in Rats. Molecular Pharmaceutics, 2014, 11, 496-504.	4.6	49
38	Population Pharmacokinetic Comparison and Pharmacodynamic Breakpoints of Ceftazidime in Cystic Fibrosis Patients and Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2010, 54, 1275-1282.	3.2	48
39	First Penicillin-Binding Protein Occupancy Patterns of Î²-Lactams and Î²-Lactamase Inhibitors in Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	48
40	Relevance of Pharmacokinetic and Pharmacodynamic Modeling to Clinical Care of Critically Ill Patients. Current Pharmaceutical Biotechnology, 2011, 12, 2044-2061.	1.6	47
41	Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria. Infectious Diseases and Therapy, 2015, 4, 391-415.	4.0	45
42	Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity. Journal of Antimicrobial Chemotherapy, 2017, 72, 1415-1420.	3.0	44
43	Aminoglycosides against carbapenem-resistantEnterobacteriaceaein the critically ill: the pitfalls of aminoglycoside susceptibility. Expert Review of Anti-Infective Therapy, 2017, 15, 519-526.	4.4	44
44	Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients. Cancer Chemotherapy and Pharmacology, 2009, 63, 1049-1063.	2.3	43
45	Application of Pharmacokinetic-Pharmacodynamic Modeling and the Justification of a Novel Fusidic Acid Dosing Regimen: Raising Lazarus From the Dead. Clinical Infectious Diseases, 2011, 52, S513-S519.	5.8	43
46	Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2016, 60, 3913-3920.	3.2	43
47	Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults. Clinical Pharmacology and Therapeutics, 2018, 104, 957-965.	4.7	43
48	Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid. British Journal of Clinical Pharmacology, 2010, 69, 167-178.	2.4	41
49	Population Pharmacokinetics of Fusidic Acid: Rationale for Front-Loaded Dosing Regimens Due to Autoinhibition of Clearance. Antimicrobial Agents and Chemotherapy, 2013, 57, 498-507.	3.2	40
50	Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model. Journal of Antimicrobial Chemotherapy, 2020, 75, 2622-2632.	3.0	39
51	Disposition, Oral Bioavailability, and Tissue Distribution of Zearalenone in Rats at Various Dose Levels. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2009, 72, 1406-1411.	2.3	38
52	Effect of different renal function on antibacterial effects of piperacillin againstPseudomonas aeruginosaevaluated via the hollow-fibre infection model and mechanism-based modelling. Journal of Antimicrobial Chemotherapy, 2016, 71, 2509-2520.	3.0	38
53	Development and validation of a liquid chromatographyâ€“mass spectrometry assay for polymyxin B in bacterial growth media. Journal of Pharmaceutical and Biomedical Analysis, 2014, 92, 177-182.	2.8	36
54	Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii : pharmacodynamics of new dosing strategies. Journal of Antimicrobial Chemotherapy, 2016, 71, 3148-3156.	3.0	36

#	Article	IF	Citations
55	High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance inAcinetobacter baumannii. Journal of Antimicrobial Chemotherapy, 2017, 72, 153-165.	3.0	36
56	Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. Clinical Pharmacology and Therapeutics, 1999, 65, 262-274.	4.7	34
57	Inhibition of flucloxacillin tubular renal secretion by piperacillin. British Journal of Clinical Pharmacology, 2008, 66, 648-659.	2.4	34
58	PEGylation Does Not Significantly Change the Initial Intravenous or Subcutaneous Pharmacokinetics or Lymphatic Exposure of Trastuzumab in Rats but Increases Plasma Clearance after Subcutaneous Administration. Molecular Pharmaceutics, 2015, 12, 794-809.	4.6	34
59	Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	34
60	Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations. Journal of Antimicrobial Chemotherapy, 2012, 67, 2182-2190.	3.0	33
61	Evaluation of Once-Daily Vancomycin against Methicillin-Resistant Staphylococcus aureus in a Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2012, 56, 682-686.	3.2	33
62	Penetration of Moxifloxacin into Bone Evaluated by Monte Carlo Simulation. Antimicrobial Agents and Chemotherapy, 2009, 53, 2074-2081.	3.2	32
63	Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas aeruginosa Determined via Mechanistic Studies and Modeling. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	31
64	Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	31
65	Bone Penetration of Amoxicillin and Clavulanic Acid Evaluated by Population Pharmacokinetics and Monte Carlo Simulation. Antimicrobial Agents and Chemotherapy, 2009, 53, 2569-2578.	3.2	30
66	Physiologically Based Pharmacokinetics of Zearalenone. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2009, 72, 1395-1405.	2.3	30
67	Nonlinear pharmacokinetics of piperacillin in healthy volunteers â€“ implications for optimal dosage regimens. British Journal of Clinical Pharmacology, 2010, 70, 682-693.	2.4	30
68	Population Pharmacokinetics of Piperacillin at Two Dose Levels: Influence of Nonlinear Pharmacokinetics on the Pharmacodynamic Profile. Antimicrobial Agents and Chemotherapy, 2012, 56, 5715-5723.	3.2	30
69	New Dosing Strategies for an Old Antibiotic: Pharmacodynamics of Front-Loaded Regimens of Colistin at Simulated Pharmacokinetics in Patients with Kidney or Liver Disease. Antimicrobial Agents and Chemotherapy, 2014, 58, 1381-1388.	3.2	30
70	Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	30
71	Front-Loaded Linezolid Regimens Result in Increased Killing and Suppression of the Accessory Gene Regulator System of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2012, 56, 3712-3719.	3.2	29
72	Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration. Journal of Antimicrobial Chemotherapy, 2014, 69, 2508-2516.	3.0	29

#	Article	IF	Citations
73	Controlling antibiotic release from mesoporous silica nano drug carriers via self-assembled polyelectrolyte coating. Journal of Materials Science: Materials in Medicine, 2015, 26, 117.	3.6	29
74	Zika Virus Replication Is Substantially Inhibited by Novel Favipiravir and Interferon Alpha Combination Regimens. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	29
75	Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii. International Journal of Antimicrobial Agents, 2016, 48, 331-336.	2.5	28
76	Effect of Half-Life on the Pharmacodynamic Index of Zanamivir against Influenza Virus Delineated by a Mathematical Model. Antimicrobial Agents and Chemotherapy, 2011, 55, 1747-1753.	3.2	27
77	Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	27
78	Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients. Cancer Chemotherapy and Pharmacology, 2009, 63, 1035-1048.	2.3	26
79	Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutablePseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2016, 71, 3157-3167.	3.0	26
80	Determination of the small RNA GcvB regulon in the Gram-negative bacterial pathogen Pasteurella multocida and identification of the GcvB seed binding region. Rna, 2018, 24, 704-720.	3.5	26
81	Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	26
82	Natural history of Acinetobacter baumannii infection in mice. PLoS ONE, 2019, 14, e0219824.	2.5	26
83	Impact of Two-Component Regulatory Systems PhoP-PhoQ and PmrA-PmrB on Colistin Pharmacodynamics in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2012, 56, 3453-3456.	3.2	25
84	The Impact of Lymphatic Transport on the Systemic Disposition of Lipophilic Drugs. Journal of Pharmaceutical Sciences, 2013, 102, 2395-2408.	3.3	25
85	Conjugation of 10 kDa Linear PEG onto Trastuzumab Fabâ€² Is Sufficient to Significantly Enhance Lymphatic Exposure while Preserving in Vitro Biological Activity. Molecular Pharmaceutics, 2016, 13, 1229-1241.	4.6	25
86	Development of a Physiologically Relevant Population Pharmacokinetic in Vitroâ€“in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation. Molecular Pharmaceutics, 2017, 14, 53-65.	4.6	24
87	Comparable Efficacy and Better Safety of Double Î²-Lactam Combination Therapy versus Î²â€‘Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	24
88	Use of Population Pharmacokinetic Modeling and Monte Carlo Simulation To Describe the Pharmacodynamic Profile of Cefditoren in Plasma and Epithelial Lining Fluid. Antimicrobial Agents and Chemotherapy, 2008, 52, 1945-1951.	3.2	23
89	Powder Strength Distributions for Understanding De-agglomeration of Lactose Powders. Pharmaceutical Research, 2012, 29, 2926-2935.	3.5	22
90	Population Pharmacokinetics and Penetration into Prostatic, Seminal, and Vaginal Fluid for Ciprofloxacin, Levofloxacin, and Their Combination. Chemotherapy, 2011, 57, 402-416.	1.6	21

#	Article	IF	Citations
91	Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	21
92	Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2019, 64, .	3.2	21
93	Modeling the Autoinhibition of Clarithromycin Metabolism during Repeated Oral Administration. Antimicrobial Agents and Chemotherapy, 2009, 53, 2892-2901.	3.2	20
94	Assessment of Bisphenol a Exposure in Korean Pregnant Women by Physiologically Based Pharmacokinetic Modeling. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2010, 73, 1586-1598.	2.3	20
95	Mechanism-Based Model of Parasite Growth and Dihydroartemisinin Pharmacodynamics in Murine Malaria. Antimicrobial Agents and Chemotherapy, 2013, 57, 508-516.	3.2	20
96	Pharmacokinetics and metabolite profiling of fimasartan, a novel antihypertensive agent, in rats. Xenobiotica, 2014, 44, 913-925.	1.1	20
97	Shape does matter: short high-concentration exposure minimizes resistance emergence for fluoroquinolones in Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2015, 70, 818-826.	3.0	20
98	Population Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans. AAPS Journal, 2015, 17, 1210-1223.	4.4	20
99	New Semiphysiological Absorption Model To Assess the Pharmacodynamic Profile of Cefuroxime Axetil Using Nonparametric and Parametric Population Pharmacokinetics. Antimicrobial Agents and Chemotherapy, 2009, 53, 3462-3471.	3.2	19
100	Competitive Inhibition of Renal Tubular Secretion of Gemifloxacin by Probenecid. Antimicrobial Agents and Chemotherapy, 2009, 53, 3902-3907.	3.2	19
101	Population Pharmacokinetics and Target Attainment of Meropenem in Plasma and Tissue of Morbidly Obese Patients after Laparoscopic Intraperitoneal Surgery. Antimicrobial Agents and Chemotherapy, 2015, 59, 6241-6247.	3.2	19
102	Clinical Regimens of Favipiravir Inhibit Zika Virus Replication in the Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	19
103	Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2016, 60, 2870-2880.	3.2	18
104	Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	18
105	Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers. Diagnostic Microbiology and Infectious Disease, 2009, 65, 130-141.	1.8	17
106	Novel Cassette Assay To Quantify the Outer Membrane Permeability of Five Î²-Lactams Simultaneously in Carbapenem-Resistant Klebsiella pneumoniae and Enterobacter cloacae. MBio, 2020, 11, .	4.1	17
107	Research priorities towards precision antibiotic therapy to improve patient care. Lancet Microbe, The, 2022, 3, e795-e802.	7.3	17
108	First Penicillin-Binding Protein Occupancy Patterns for 15 Î²-Lactams and Î²-Lactamase Inhibitors in Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, 2020, 65, .	3.2	16

#	Article	IF	Citations
109	Evaluation of Meropenemâ€Ciprofloxacin Combination Dosage Regimens for the Pharmacokinetics of Critically Ill Patients With Augmented Renal Clearance. Clinical Pharmacology and Therapeutics, 2021, 109, 1104-1115.	4.7	16
110	The time course of drug effects. Pharmaceutical Statistics, 2009, 8, 176-185.	1.3	15
111	Four Decades of Î²-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis. Clinical Pharmacokinetics, 2019, 58, 143-156.	3.5	15
112	ABT-773: Pharmacokinetics and Interactions with Ranitidine and Sucralfate. Antimicrobial Agents and Chemotherapy, 2003, 47, 1129-1131.	3.2	14
113	Evaluation of enrofloxacin use in koalas (<scp>P</scp>hascolarctos cinereus) via population pharmacokinetics and <scp>M</scp>onte <scp>C</scp>arlo simulation. Journal of Veterinary Pharmacology and Therapeutics, 2014, 37, 301-311.	1.3	14
114	Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant Acinetobacter baumannii. International Journal of Antimicrobial Agents, 2016, 48, 719-724.	2.5	14
115	Pharmacodynamics of dose-escalated â€˜front-loadingâ€™ polymyxin B regimens against polymyxin-resistant mcr-1-harbouring Escherichia coli. Journal of Antimicrobial Chemotherapy, 2017, 72, 2297-2303.	3.0	14
116	Pharmacokinetics of 1,4-Butanediol in Rats: Bioactivation to Î³-Hydroxybutyric Acid, Interaction with Ethanol, and Oral Bioavailability. AAPS Journal, 2008, 10, 56-69.	4.4	13
117	Novel Rate-Area-Shape Modeling Approach To Quantify Bacterial Killing and Regrowth for In Vitro Static Time-Kill Studies. Antimicrobial Agents and Chemotherapy, 2015, 59, 381-388.	3.2	13
118	Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	13
119	Prolonged and continuous antibacterial and anti-biofilm activities of thin films embedded with gentamicin-loaded mesoporous silica nanoparticles. Applied Nanoscience (Switzerland), 2018, 8, 1471-1482.	3.1	13
120	Novel extended in vitro-in vivo correlation model for the development of extended-release formulations for baclofen: From formulation composition to in vivo pharmacokinetics. International Journal of Pharmaceutics, 2019, 556, 276-286.	5.2	13
121	Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?. AAPS Journal, 2021, 23, 48.	4.4	13
122	Evaluation of the pharmacokineticsâ€“pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selection. Diagnostic Microbiology and Infectious Disease, 2011, 70, 101-111.	1.8	12
123	Population Pharmacokinetics and Target Attainment of Ertapenem in Plasma and Tissue Assessed via Microdialysis in Morbidly Obese Patients after Laparoscopic Visceral Surgery. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	12
124	Aminoglycoside-resistance gene signatures are predictive of aminoglycoside MICs for carbapenem-resistant Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 2022, 77, 356-363.	3.0	12
125	Stability and controlled antibiotic release from thin films embedded with antibiotic loaded mesoporous silica nanoparticles. RSC Advances, 2015, 5, 107839-107846.	3.6	11
126	Lessons learned in the development of sustained release penicillin drug delivery systems for the prophylactic treatment of rheumatic heart disease (RHD). Drug Delivery and Translational Research, 2018, 8, 729-739.	5.8	11

#	Article	IF	Citations
127	FDA Public Workshop Summary: Advancing Animal Models for Antibacterial Drug Development. Antimicrobial Agents and Chemotherapy, 2020, 65, .	3.2	11
128	Comparable Population Pharmacokinetics and Pharmacodynamic Breakpoints of Cefpirome in Cystic Fibrosis Patients and Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2011, 55, 2927-2936.	3.2	10
129	Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial. Journal of Antimicrobial Chemotherapy, 2016, 71, 2234-2240.	3.0	10
130	Combating Carbapenem-Resistant Acinetobacter baumannii by an Optimized Imipenem-plus-Tobramycin Dosage Regimen: Prospective Validation via Hollow-Fiber Infection and Mathematical Modeling. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	10
131	Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding. Pharmaceutics, 2019, 11, 286.	4.5	10
132	Combating Multidrugâ€Resistant Bacteria by Integrating a Novel Target Site Penetration and Receptor Binding Assay Platform Into Translational Modeling. Clinical Pharmacology and Therapeutics, 2021, 109, 1000-1020.	4.7	10
133	Vom Farbstoff zum Rezeptor: Paul Ehrlich und die Chemie. Nachrichten Aus Der Chemie, 2004, 52, 777-782.	0.0	9
134	Quantitative Determination of Absorption and First-Pass Metabolism of Apicidin, a Potent Histone Deacetylase Inhibitor. Drug Metabolism and Disposition, 2014, 42, 974-982.	3.3	9
135	Generating Genotype-Specific Aminoglycoside Combinations with Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2021, 65, e0069221.	3.2	9
136	Emergence of Resistance to Ceftazidime-Avibactam in a Pseudomonas aeruginosa Isolate Producing Derepressed bla _{PDC} in a Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	8
137	Prediction of human pharmacokinetics and tissue distribution of apicidin, a potent histone deacetylase inhibitor, by physiologically based pharmacokinetic modeling. Cancer Chemotherapy and Pharmacology, 2011, 68, 465-475.	2.3	7
138	Population data analysis of dissolution time profiles: Assessment of physicochemical properties of the drug, drug particles and the pharmaceutical formulation. European Journal of Pharmaceutical Sciences, 2015, 78, 245-254.	4.0	7
139	Combination Regimens of Favipiravir Plus Interferon Alpha Inhibit Chikungunya Virus Replication in Clinically Relevant Human Cell Lines. Microorganisms, 2021, 9, 307.	3.6	7
140	Pharmacokinetics of Ertapenem in Colorectal Tissue. Chemotherapy, 2011, 57, 437-448.	1.6	6
141	First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers. European Journal of Pharmaceutical Sciences, 2018, 123, 416-428.	4.0	6
142	Emergence of Polymyxin B Resistance Influences Pathogenicity in Pseudomonas aeruginosa Mutators. Antimicrobial Agents and Chemotherapy, 2015, 59, 4343-4346.	3.2	5
143	Defining the Active Fraction of Daptomycin against Methicillin-Resistant Staphylococcus aureus (MRSA) Using a Pharmacokinetic and Pharmacodynamic Approach. PLoS ONE, 2016, 11, e0156131.	2.5	5
144	Regional Absorption of Fimasartan in the Gastrointestinal Tract by an Improved in situ Absorption Method in Rats. Pharmaceutics, 2018, 10, 174.	4.5	5

#	Article	IF	Citations
145	Cascade Impactor Equivalence Testing: Comparison of the Performance of the Modified Chi-Square Ratio Statistic (mCSRS) with the Original CSRS and EMAâ€™s Average Bioequivalence Approach. AAPS PharmSciTech, 2019, 20, 249.	3.3	5
146	Characterizing the time-course of antihypertensive activity and optimal dose range of fimasartan via mechanism-based population modeling. European Journal of Pharmaceutical Sciences, 2017, 107, 32-44.	4.0	4
147	Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine. Molecules, 2017, 22, 1515.	3.8	4
148	Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia coli. Diagnostic Microbiology and Infectious Disease, 2018, 91, 69-76.	1.8	4
149	Comparable Bioavailability and Disposition of Pefloxacin in Patients with Cystic Fibrosis and Healthy Volunteers Assessed via Population Pharmacokinetics. Pharmaceutics, 2019, 11, 323.	4.5	4
150	Evaluation of Tobramycin and Ciprofloxacin as a Synergistic Combination Against Hypermutable Pseudomonas Aeruginosa Strains via Mechanism-Based Modelling. Pharmaceutics, 2019, 11, 470.	4.5	4
151	Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling. Antimicrobial Agents and Chemotherapy, 2022, 66, aac0220321.	3.2	4
152	Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against Pseudomonas aeruginosa for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection Model. Antibiotics, 2022, 11, 101.	3.7	4
153	Informing and Validating Translational Mechanismâ€Based Models for Antibiotics by Experimental and Computational Approaches. Clinical Pharmacology and Therapeutics, 2021, 110, 1426-1428.	4.7	3
154	Synthesis and Structureâ€“Activity Relationship of Thioacetamide-Triazoles against Escherichia coli. Molecules, 2022, 27, 1518.	3.8	3
155	Placental transfer and mammary excretion of a novel angiotensin receptor blocker fimasartan in rats. BMC Pharmacology & Toxicology, 2016, 17, 35.	2.4	2
156	Development of an Enantioselective and Biomarker-Informed Translational Population Pharmacokinetic/Pharmacodynamic Model for Etodolac. AAPS Journal, 2017, 19, 1814-1825.	4.4	2
157	Effect of Sipjeondaebo-Tang on the Pharmacokinetics of S-1, an Anticancer Agent, in Rats Evaluated by Population Pharmacokinetic Modeling. Molecules, 2017, 22, 1488.	3.8	2
158	Population Pharmacokinetics of a Novel Histone Deacetylase Inhibitor, Cyclo{(2S)-2-Amino-8-[(Aminocarbonyl)Hydrazono] Decanoyl-1-L-Tryptophyl-L-Isoleucyl-(2R)-2-Piperidinecarbonyl} (SD-2007), and Its Metabolic Conversion to Apicidin after Intravenous Injection and Oral Administration in Rats. Chemotherapy, 2011, 57, 259-267.	1.6	1
159	Translational Modeling of Antibacterial Agents. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , 371-402.	0.6	0
160	Systematic Evaluation of the Effect of Formulation Variables on In Vitro Performance of Mometasone Furoate Suspension-Metered Dose Inhalers. AAPS Journal, 2022, 24, 9.	4.4	0